Much of the improvement in the survival of individuals with cystic fibrosis (CF) is due to advancements in antimicrobial treatments. New aerosolized antibiotic formulations have recently been introduced (such as inhaled aztreonam), and others are in development (inhaled levofloxacin and liposomal amikacin). Licenced dry powder formulations include tobramycin inhalation powder and dry powder colistimethate (available in Europe). Although inhaled antibiotics have the advantage of being able to deliver high intrapulmonary concentrations of drug, antimicrobial resistance can still develop and is a concern in CF. Antimicrobial resistance might be mitigated by using non-antibiotic treatments, antibiotic adjuvants, which have activity against bacteria. Examples include agents such as gallium, antimicrobial peptides and antibiofilm compounds such as alginate oligosaccharides (OligoG) and garlic. Vaccination strategies and antibody therapy (IgY) against P. aeruginosa have also been attempted to prevent initial infection with this organism in CF. Although aggressive and long-term use of antibiotics has been crucial in slowing lung function decline and improving survival in people with CF, it has added a significant burden of care and associated toxicities in these individuals. Careful surveillance and the use of preventative strategies for antibiotic related toxicity (such as nephrotoxicity and ototoxicity) are essential. Continued development of effective antimicrobial agents that can function in the conditions encountered in the CF lung, such as against bacterial biofilm growth and under anaerobic conditions, is needed.
Introduction
There has been significant improvement in the survival of individuals with cystic fibrosis (CF) over the last half century, from a median age of survival of 5 years in the 1970s to approximately 40 years of age as of 2011. The reasons for the improvement in clinical outcomes are multifactorial but include the intense use of antibiotic therapy in this patient population.
Despite these improvements, however, the majority of CF deaths still occur in young adulthood, typically between the ages of 21-30 years (1) . Continued development and optimal usage of new antimicrobial compounds (including antibiotic combinations) is essential to improve the quality and survival of people with CF.
In the last several years, there have been an increasing number of available antibiotics, of different classes and formulations, for the treatment of pulmonary infections in CF patients. This review will discuss some of the new antibiotics including novel methods of delivery, the implications of the development of antimicrobial resistance, potential non-antibiotic treatments of CF lung infections and the lifetime burden and toxicity of repeated courses of antibiotic therapy.
New antimicrobials and methods of delivery

Several new inhalational antibiotics have recently become available for the treatment
Pseudomonas aeruginosa pulmonary infections in CF patients (Table 1) . Antibiotics delivered via aerosolization have the advantage of being able to achieve very high intrapulmonary concentrations with few associated systemic side effects.
Inhaled aztreonam
Inhaled aztreonam, commercially known as AZLI or Cayston, is currently on the market for the treatment of Pseudomonas aeruginosa infections in CF patients. It is an aerosolized formulation of the monobactam antibiotic aztreonam and lysine. In contrast, the intravenous formulation of aztreonam contains arginine which can cause airway inflammation. The initial randomized controlled trial of inhaled aztreonam was performed in 211 individuals with CF 6 years of age or older with P. aeruginosa infection (2) . After a 28 day course of tobramycin inhalation solution (TIS), patients were randomized to receive either 75 mg of inhaled aztreonam three times daily or placebo for 28 days. Inhaled aztreonam treatment increased the median time to requiring additional anti-pseudomonal antibiotics for symptoms of pulmonary exacerbation by 21 days, compared with placebo (p=0.007). In addition, inhaled aztreonam improved mean symptom scores (p=0.02), forced expiratory volume in 1 second (FEV 1 ) (6.3%, p=0.001) and sputum P. aeruginosa bacterial density (-0.66 log 10 CFU/g, p=0.006) compared with placebo.
The drug was well tolerated and the in vitro susceptibilities of P. aeruginosa isolates to aztreonam from baseline to end of therapy were comparable. Similar improvements in respiratory symptoms, lung function and microbiological outcomes were also observed in another Phase II trial of inhaled aztreonam in CF patients with moderate to severe lung disease and no recent use of anti-pseudomonal antibiotics or azithromycin (3) . In CF individuals greater than 6 years of age and mild lung disease (FEV 1 >75% predicted), however, the effects of inhaled aztreonam treatment were more modest with no statistically significant improvement in respiratory symptoms and only a 2.7% improvement in relative FEV 1 % predicted (p=0.021) compared to placebo treatment (4) . When compared to TIS in an open-label, parallel-group international trial in 273 patients with CF, after 3 cycles of inhaled aztreonam (28 day on; 28 5 days off), the mean change in FEV 1 was 2.05% for aztreonam compared to -0.66% for TIS (p=0.002) (5) . Patients in the aztreonam arm also had fewer respiratory hospitalizations and additional anti-pseudomonal antibiotics compared to the TIS arm. However, it is important to note that over 85% of subjects had already received at least 3 cycles of TIS before randomization and the beneficial effects of inhaled tobramycin are known to diminish over time. This so-called honeymoon effect is not restricted to aminoglycosides and is not explained by the development of in vitro resistance (6) . In addition to studies in CF patients with P. aeruginosa infection, the efficacy of inhaled aztreonam has been examined in CF individuals with chronic Burkholderia cepacia complex infection (7) . A double-blind, placebo-controlled, 24 week trial of continuous inhaled aztreonam versus placebo treatment was performed in 100 CF patients with chronic Burkholderia spp. infection. By 24 weeks of treatment, there was no significant difference between arms in terms of change in FEV 1 , number of respiratory exacerbations or hospitalizations. Importantly, there was also no significant decrease in sputum bacteria density change in treated patients compared to placebo. In vitro studies have demonstrated that aztreonam, as a ß-lactam that functions best against rapidly dividing organisms, may not have very good activity against CF organisms when grown as a biofilm, in contrast to aminoglycosides, for example (8).
Levofloxacin inhalation solution
Aerosolized levofloxacin is another new pharmaceutical agent developed for the teatment of P. aeruginosa pulmonary infections in patients with CF. Levofloxacin is a second generation fluoroquinolone that causes cell death by inhibiting topoisomerase, an enzyme required for DNA synthesis (9) . It has properties that render it particularly effective against bacterial infections in 6 the CF lung. Thickened mucus layers in the lung of CF patients have been shown to contain areas of low oxygen tension, for example (10) . In vitro studies of the effect of oxygen limitation on antimicrobial activity against P. aeruginosa demonstrate that, unlike tobramycin, amikacin and aztreonam, P. aeruginosa minimum inhibitory concentration (MICs) and time-kill curves for levofloxacin are similar under aerobic and anaerobic conditions (11) . The same investigators have confirmed that, in comparison to aztreonam and aminoglycosides, levofloxacin has the most rapid rate of killing among P. aeruginosa isolates, is more potent against P. aeruginosa biofilms and its bactericidal activity is not affected by sputum (12) . Additional in vitro studies have suggested that inhaled levofloxacin may also have anti-inflammatory effect (13) .
Levofloxacin produced a dose-dependent reduction of both TNF-α and P. aeruginosa lipopolysaccharide-induced IL-6 and IL-8 levels in cultured human airway epithelial cells. Phase I studies of safety, tolerability and pharmacokinetic parameters of inhaled levofloxacin in stable CF patients showed the drug to be safe, resulting in low serum levels (approximately 16% of serum levels after an oral dose). This should result in a very low risk of systemic toxicities such as tendinopathy or arthropathy. However, very high sputum concentrations were achieved, in the order of 4,000 µg/ml (14) . A subsequent phase II randomized, placebo controlled study of 151 CF patients with P. aeruginosa infection demonstrated that inhaled levofloxacin 240 mg twice daily for 28 days (delivered via eFlow nebulizer) resulted in an 8.7% increase in FEV 1 percent predicted compared to placebo (p=0.003) (15) . A phase III, open-label, randomized noninferiority study comparing inhaled levofloxacin 240 mg twice daily versus tobramycin inhalation solution 300 mg twice daily over three 28 day on/off cycles in 282 CF patients with chronic P. aeruginosa infection demonstrated no significant difference in the change in FEV 1 % predicted between the groups (16) . In addition, although there was no significant difference 7 between the groups in time to symptom-defined exacerbation, subjects treated with inhaled levofloxacin solution had a longer time to adminstration of antibiotics (p=0.04) and a lower proportion of subjects hospitalized for a respiratory exacerbation (p=0.04) than those treated with inhaled tobramycin. The number of adverse events were similar between the two groups; dysgeusia (taste distortion) was the most common adverse event in the inhaled levofloxacin group.
Tobramycin inhalation powder
In addition to new types of antibiotics of differing classes, there have also been developments in the way these drugs are formulated and delivered. A currently available example is tobramycin inhalation powder (TIP). New developments in particle manufacturing have allowed tobramycin to now be formulated as a dry powder. Tobramycin inhalation powder (TIP) has the advantages of being able to be delivered very quickly (in approximately 5 minutes) using a "podhaler TM " inhalation device and having good lung delivery (17) . Initial pharmacokinetic studies demonstrated that TIP could achieve higher maximal sputum concentrations (measured 30 minutes after TIP administration) (1,092+1,052 µg/g) compared to TIS (737+1,028 µg/g), although with a wide standard deviation (18) . In the phase III EVOLVE trial, TIP (112 mg twice daily) was compared to placebo in CF patients chronically infected with P. aeruginosa (19) . In comparison to placebo, TIP significantly improved FEV 1 , reduced sputum P. aeruginosa density and decreased respiratory related hospitalization. The most common adverse event was cough but this was higher in patients receiving placebo (26%) versus TIP (13%). TIP was not associated with ototoxicity or nephrotoxicity. Subsequently, the EAGER trial was conducted: a non-inferiority study to assess the safety and efficacy of TIP (112 mg 8 twice daily) compared to TIS (300 mg/5 ml twice daily) in chronic P. aeruginosa infected CF patients (20) . TIP was comparable to TIS with similar increases in FEV 1 and similar rates of hospitalizations for respiratory-related events. Sputum P. aeruginosa density was reduced more in TIP-treated patients relative to TIS-treated patients (-1.6 log 10 vs -0.92 log 10 CFU/g for mucoid isolates and -1.77 log 10 vs -0.73 log 10 CFU/g for nonmucoid isolates). In addition, TIP achieved higher mean sputum concentrations (measured 30 minutes post dose) than TIS (1979+2770 µg/g vs 1074+1182 µg/g). The most common adverse event reported was cough which was higher in TIP (25%) than TIS (4%) treated patients. However, the rate of bronchospasm, nephrotoxicity, ototoxicity and serious adverse events were similar in both groups.
Colistin inhalation powder
Colistimethate sodium (colistin), a cationic polypeptide antibiotic (a polymyxin) which functions by disrupting the bacterial cell membrane, can also be delivered as a dry powder. It is commercially known as Colobreathe dry powder for inhalation. Colobreathe is an encapsulated dry-powder formulation administered using a hand-held inhaler (Turbospin). Colobreathe comes as capsules containing the equivalent of 125 mg colistimethate sodium (1 662 500 IU) in fine particle form. One inhaled capsule delivers the equivalent of a nebulised dose (> 2 MU). A Phase
II, randomized open-label study was conducted in CF patients ages 6 years and older with chronic P. aeruginosa infection (21) . After at least two 28 days of on-off TIS cycles, 380 subjects were randomized to either one capsule of Colobreathe dry powder for inhalation twice daily (without interruption) or three 28 day cycles of TIS (300 mg/5 ml) delivered via PARI nebulizer twice daily for a total study duration of 24 weeks. After 24 weeks, the adjusted mean difference between Colobreathe versus TIS in change in FEV 1 % predicted was -0.97% (95% CI -2.74% to 0.86%), favouring TIS. This did not exceed the preset non-inferiority limit of the 95% CI (-3%). Few colistin-resistant P. aeruginosa isolates emerged and adverse events were similar in both groups. Although more patients in the Colobreathe group rated their device as easy to use compared to the TIS group, the improvement in lung function over the 6 month study period was negligible in both treatment arms.
Inhaled liposomal amikacin
Another novel method of delivery is the packaging of antibiotics within liposomes for
aerosolization. An example of this is inhaled liposomal amikacin, otherwise known as Arikace.
Arikace contains high concentrations of aqueous, water soluble amikacin, an aminoglycoside, encased within a liposome (22). The liposome is composed of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and cholesterol which makes it very similar to surfactant, allowing it to be cleared from the lungs through a common pathway (22). Because the liposome is very small and has a neutral charge (shielding the positively charged amikacin from the negatively charged CF sputum), the drug is able to effectively penetrate into CF sputum and bacterial biofilms (23) .
Once at the site of infection, liposomes release the active drug, amikacin, upon exposure to rhamnolipids, a by-product of the P. aeruginosa bacteria itself. Phase I studies were done in 24 
Implications of antimicrobial resistance
Definition of resistance and effects of sub-inhibitory drug concentrations
Current definitions of bacterial resistance rely on antibiotic concentrations achieved by systemic therapy (oral or intravenous drug administration). "Breakpoints' by which resistance is defined by the Clinical Laboratory Standards Institute (CLSI) are therefore generally quite low, requiring, for example, a minimum inhibitory concentration (MIC) of tobramycin of < 4 µg/ml for a P. aeruginosa isolate to be deemed susceptible (26) . However, aerosolized antibiotics can achieve significantly higher sputum concentrations than intravenous antibiotics, in the order of 100 fold greater (27) . Thus, the clinically relevant definitions of resistance based on nebulized
delivery have yet to be determined (28). 
Consequences of antimicrobial resistance
Antimicrobial resistance may still be relevant in CF and has potential clinical implications. Although in vitro antimicrobial susceptibility testing, whether done on planktonic abscessus isolates with macrolides for 14 days to detect inducible mechanisms of resistance. A more rapid, molecular technique that could detect all the genes encoding mechanisms of antimicrobial resistance within a bacterial genome has potential future clinical applications.
Effects on the microbiome
Antibiotics not only have effects on the predominant bacterial pathogen in an individual's lung, but also on the multitude of other species that are known to exist as part of the CF lung microbiome. Changes in the microbiome in one location of the body, such as the gut, may even influence the bacterial composition in the lung (42) . It is now well recognized that the CF pulmonary microbiota is composed of a diverse polymicrobial community that interact with one another and are influenced by repeated, spectrum courses of antimicrobial therapy (43) .
Organisms that are not routinely identified on CF cultures, such as anaerobes, have been shown, not surprisingly, to have reduced susceptibility to antibiotics typically used to treat CF patients (44) . In a study of adult CF patients, cultured Prevotella isolates were significantly more resistant in vitro to amoxicillin-clavulanate and doxycycline than isolates from healthy adults (45) . Use of antibiotics is the primary driver of decreased microbiome diversity in the CF lung (46) . In an analysis of the effect of antibiotic use on microbial diversity in CF, intravenous antibiotic use, rather than oral or inhaled, had the highest probability of effecting greater change in community diversities, presumably due to the type of antibiotic used (eg. meropenem), with wide spectrums of action (47) . Several investigators have studied the changes in the composition of the pulmonary microbiome at the onset of a CF exacerbation and have failed to identify any clear pattern to explain their occurrence (48) (49) . One group did observe an increase in the relative abundance of Gemella species at exacerbation, suggesting that this anaerobe may be involved in triggering a pulmonary exacerbation (50) . Antimicrobial treatment of pulmonary exacerbations has been associated with very early effects on the CF microbiome (as early as day 3 of treatment) including significant reductions in the relative abundance of Pseudomonas which correlates with improvements in FEV 1 % predicted (51) (52) . In contrast, the decrease in anaerobic bacteria with antibiotic treatment in more variable and less strongly associated with improvements in lung function (52) (53) . Regardless, the pulmonary microbiome quickly returns to pre-treatment states following the end of antimicrobial treatment, indicating that it is quite resilient to change (49) . Whether these combined results suggest inadequate treatment of dominant pathogens such as P. aeruginosa or potentially more appropriate, alternative targets such as anaerobes, is currently unknown. To answer these questions, further research, using large numbers of longitudinally collected samples at multiple time points with detailed corresponding antibiotic history, is required.
Non-antibiotic treatments
Antimicrobial resistance might be further prevented by using non-antibiotic treatments which have activity against bacterial species; these include the use of antibiotic adjuvants. These are a diverse group of novel agents which act by increasing the organism's antibiotic susceptibility; by reducing its virulence; or by rendering the organism more susceptible to the host immune system (54) . These include agents such as gallium, antimicrobial peptides and antibiofilm compounds. Additionally, vaccination strategies against P. aeruginosa have been attempted to prevent initial infection with this organism.
Gallium metal
Gallium metal, structurally similar to iron (Fe), can substitute itself in many of the Fe dependent pathways essential in the growth and functioning of many bacteria such as P.
aeruginosa (55) . In such a way, gallium can inhibit the growth of bacteria such as P. aeruginosa.
In vitro studies have shown that a liposomal gentamicin formulation with gallium metal is more effective than gentamicin alone in eradicating antibiotic-resistant P. aeruginosa isolates from CF patients, grown planktonically or as a biofilm (56) . In fact, the liposomal gallium-gentamicin combination was the only formulation that completely eradicated biofilms and blocked quorumsensing molecules at very low concentrations of gentamicin (0.94 mg/L). Gallium is thus currently being investigated for its antibacterial properties and its potential applications in the treatment of pulmonary infections in CF.
Antimicrobial peptides
Another However, despite their rapid and wide spectrum of activity, even mechanisms of resistance against antimicrobial peptides have been identified (62) (63) .
Anti-biofilm compounds
Much of the difficulty encountered in treating pulmonary infections in CF patients is due to the fact that bacteria such as P. aeruginosa grow as a biofilm in the airways of CF patients with chronic pulmonary infections (64) (65) . When infection becomes chronic, Pseudomonas grow as biofilms; namely, bacterial populations embedded in a complex matrix comprising exopolysaccharide (bacterial alginate), airway mucins and neutrophil-derived DNA. The biosynthesis and regulation of bacterial alginate (which influences the architecture of the biofilm) is complex and involves mutations in bacterial regulatory genes (muc mutations) and an important population-based regulatory system known as quorum sensing (QS) (66-68). The quorum-sensing genes (LasR and RhlR) encode for virulence factors such as proteases, rhamnolipids, hemolysins, iron-scavenging pigments, catalase and superoxide dismutase (69).
Biofilms are highly resistant to killing by antibiotics for many reasons. This antimicrobial resistance is due in part to the polysaccharide matrix which retards the diffusion of antibiotics, but more importantly results in a slow rate of bacterial growth within the matrix, and in the case of aminoglycosides, to electrolyte interference with antibiotic activity (70) . Much work has therefore been done to develop compounds that can inhibit or disrupt bacterial biofilms to allow antibiotics to work. An example of this is alginate oligosaccharides (OligoG), a biopolymer which is found in brown algae. In vitro studies have demonstrated that OligoG can not only inhibit biofilm formation and disrupt established 24-hour biofilms but also potentiate antibiotic effects, decreasing the minimum inhibitory concentration (MIC), up to 512-fold, for macrolides, β-lactams and tetracyclines, against important multidrug resistant pathogens such as P.
aeruginosa and B. cepacia complex (71) . Although its mechanism of action is not yet fully understood, it is postulated that it disrupts the bacterial membrane by chelating cations, allowing antibiotics to effectively penetrate the cell. Phase II studies of inhaled dry powder OligoG in adult patients with CF are currently underway (clinicaltrials.gov identifier NCT02157922).
Another potentially useful anti-biofilm agent is garlic and garlic extracts, in particular, the compounds allicin and ajoene. Using high-throughput screening, garlic was discovered to inhibit quorum sensing through a presently unknown mechanism (72). When P. aeruginosa was grown in vitro in continuous-culture flow chambers, the garlic-treated biofilms, in comparison to untreated controls, were susceptible to both tobramycin and polymorphonuclear leukocyte killing (73) . In addition, in a mouse model of P. aeruginosa pulmonary infection, the treated group had a greater decrease in lung bacterial burden compared to the placebo group. When tested in a trial of 26 CF patients, there was a greater decline in FEV 1 from baseline for patients in the placebo arm compared to the garlic treated arm and a greater increase in weight in the garlic treated arm compared to the placebo arm, although neither of these differences between treatment groups was significant (74) . 
.
Immunization against P. aeruginosa
Given the intrinsic difficulties in treating established P. aeruginosa chronic infections in the CF lung, preventing initial infection through immunization is an attractive alternative. is an important component to the improvement of outcomes; high adherence with tobramycin inhalation solution, for example, has been shown to be associated with a decreased risk of hospitalization (86) . Unfortunately, studies have demonstrated that only 32% of CF patients are fully adherent to prescribed nebulized antibiotic treatment (87) . Chip-based recording nebulizers can store data such as treatment date, time, duration and completeness of dose, that can then be downloaded to generate an accurate report of adherence (88) . Using this type of information, it is possible to provide patients with feedback and adjust treatment schedules to hopefully improve compliance (89) .
Antimicrobial toxicities
In addition to the burden of lifelong antimicrobial therapies, CF patients have to contend with the associated toxicities as well. These toxicities are most apparent for aminoglycosides, for which the primary side effects are nephrotoxicity and ototoxicity. Intravenous aminoglycosides are a mainstay of therapy for the treatment of pulmonary exacerbations in CF. Serum drug levels should be monitored to avoid nephrotoxicity. Given that aminoglycosides function in a concentration dependent manner, once daily dosing is likely to be more efficacious as well as 
Conclusions
The advantages of aerosolized therapy suggest that this is an important area for future drug development. Antimicrobials should also be designed to be effective in the conditions encountered in the CF lung such as against bacterial biofilm growth, under anaerobic conditions and be able to penetrate sputum. With the discovery of small molecules that can restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR), it is hoped that one day individuals with CF will no longer be afflicted with these difficult to treat pulmonary infections caused by opportunistic, multidrug resistant pathogens. However, until the underlying defect can be corrected in all CF patients, antimicrobial treatments that decrease the bacterial contribution to the underlying pulmonary hyper-inflammatory state are vital to the quality of life and survival of individuals with CF.
